BioSpace News Archive

Recce Pharmaceuticals Ltd today announced it has been issued a trademark registration for RECCE ® from the Canadian Intellectual Property Office, strengthening its global intellectual property (IP) portfolio.

Gamida Cell Ltd. today announced that the company will release its financial results for the fourth quarter and full year ended December 31, 2023 and provide an update on the company on Wednesday, March 27, 2024.

Brain–computer interface company Precision Neuroscience Corporation announced the launch of two new clinical study sites, at Mount Sinai Health System and Perelman School of Medicine at the University of Pennsylvania.

Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that it will phase down its preclinical oncology research activities.

GE HealthCare will showcase its latest technologies in image guiding solutions, surgery, ultrasound and CT-navigation at the upcoming 2024 Society of Interventional Radiology Annual Scientific Meeting taking place March 23-28 in Salt Lake City, UT.

RedDrop Dx, Inc., Innosphere Ventures Client Company, is pleased to announce that its innovative blood collection device, RedDrop One, has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for prescription use.

According to Vision Research Reports, the monoclonal antibodies market is poised to grow at a CAGR of 11.07% from 2024 to 2033.

Marker Therapeutics, Inc. (Nasdaq: MRKR) today announced that Juan Vera, M.D., President and Chief Executive Officer of Marker Therapeutics, will present at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference.

The ALS Association, the leading national non-profit organization dedicated to fighting ALS on every front, is excited to announce its inaugural ALS Nexus Conference, taking place July 14-17, 2024 at The Gaylord Texan Resort & Conference Center in Grapevine, Texas.

GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today reported its full year 2023 consolidated financial results, as approved by the Board of Directors on March 21, 2024.